All lobbying filings

KYLE HOUSE GROUP

KYLE HOUSE GROUP filed a Q3 termination report for INTERNATIONAL AIDS VACCINE INITIATIVE on October 23, 2025, reporting $10,000 in lobbying income.

Lobbying for INTERNATIONAL AIDS VACCINE INITIATIVE · nonprofit scientific research organization dedicated to addressing global health challenge

All filings by KYLE HOUSE GROUP · Everything INTERNATIONAL AIDS VACCINE INITIATIVE has reported

Filing · LD-2 quarterly report Q3 termination

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 23, 2025

Income

$10,000

What the client paid this registrant for the period.

Client based in

New York

Representation ended

Sep 30, 2025

The registrant reported terminating its work for this client.

Official filing document

Lobbyists on this filing 2

MICHAEL MILLER

Previously held: Policy Director, U.S. Senate Committee on Foreign Relations; Senior Advisor, Office of the U.S. Secretary HHS; Deputy Assistant Administrator for Global Health, USAID; Director for African Affairs,NSC; Legislative Assistant, Senator Bill Frist
JULIAN FLEISCHMAN

Previously held: Senior Legislative Assistant, Rep. Peter Meijer; Legislative Assistant, Rep. Brian Mast

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Budget/Appropriations

Education and advocacy on the International AIDS Vaccine Initiative and U.S. government investments in vaccine development programs.

Health Issues

Education and advocacy on the International AIDS Vaccine Initiative and U.S. government investments in vaccine development programs.

Foreign Relations

Education and advocacy on the International AIDS Vaccine Initiative and U.S. government investments in vaccine development programs.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.